The factor of differentiation--i.e. systemic morphogen of connective tissue (SMCT)--have been discovered in bone marrow and blood serum of healthy humans. SMCT calls forth the differentiation of mesodermal cell types in early embryonic amphibian cells. These cell types are the following: notochords, muscles, mesothelium, blood cells, mesenchyme. Under the influence of the punctates of bone marrow the frequency of muscle and blood cell appearance is not constant, which might be the consequence of the individual variability of SMCT. Under the influence of bone marrow and blood serum in patients with acute lymphoblastic, monoblastic and myelomonoblastic leukemia the embryonic cells differentiate only into atypical epidermis, which proves the absence of the SMCT activity in the sources used. In some cases under the influence of bone marrow from patients having the same disease the early embryonic cells differentiate into mesodermal cell types, which normally appear under the low concentration of SMCT. This was observed however only in those cases when bone marrow or blood serum have been taken from patients in the state of remission. In patients with remission the correlation is observed between the activity of factor of differentiation in bone marrow and that of blood serum.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A non-conditioned bone marrow transplantation mouse model to study clonal hematopoiesis and myeloid malignancies.
Exp Hematol Oncol
January 2025
Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Clonal hematopoiesis of indeterminate potential (CHIP) is a condition where blood or bone marrow cells carry mutations associated with hematological malignancies. Individuals with CHIP have an increased risk of developing hematological malignancies, atherosclerotic cardiovascular disease, and all-cause mortality. Bone marrow transplantation (BMT) of cells carrying CHIP mutations into irradiated mice are useful procedures to investigate the dynamics of clonal expansion and potential therapeutic strategies, but myeloablative conditioning can induce confounding effects.
View Article and Find Full Text PDFSevere pregnancy-associated atypical hemolytic uremia syndrome in the context of the COVID-19 pandemic: a novel survival case report.
BMC Pregnancy Childbirth
January 2025
Department of Intensive Care Medicine, Army Medical Center of PLA, No. 10 Changjiang Road, Yuzhong District, Chongqing, 400010, People's Republic of China.
Background: Pregnancy-associated atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) caused by uncontrolled activation of the complement system during pregnancy or the postpartum period. In the intensive care unit, aHUS must be differentiated from sepsis-related multiple organ dysfunction, thrombotic thrombocytopenic purpura (TTP), hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome. Early recognition of aHUS is critical for effective treatment and improved prognosis.
View Article and Find Full Text PDFSingle cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives.
Mol Med
January 2025
Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, 8174673461, Iran.
Acute myeloid leukemia (AML) is caused by altered maturation and differentiation of myeloid blasts, as well as transcriptional/epigenetic alterations, all leading to excessive proliferation of malignant blood cells in the bone marrow. Tumor heterogeneity due to the acquisition of new somatic alterations leads to a high rate of resistance to current therapies or reduces the efficacy of hematopoietic stem cell transplantation (HSCT), thus increasing the risk of relapse and mortality. Single-cell RNA sequencing (scRNA-seq) will enable the classification of AML and guide treatment approaches by profiling patients with different facets of the same disease, stratifying risk, and identifying new potential therapeutic targets at the time of diagnosis or after treatment.
View Article and Find Full Text PDFNuclear farnesoid X receptor protects against bone loss by driving osteoblast differentiation through stabilizing RUNX2.
Bone Res
January 2025
Department of Orthopedic Surgery, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
The delicate balance between bone formation by osteoblasts and bone resorption by osteoclasts maintains bone homeostasis. Nuclear receptors (NRs) are now understood to be crucial in bone physiology and pathology. However, the function of the Farnesoid X receptor (FXR), a member of the NR family, in regulating bone homeostasis remains incompletely understood.
View Article and Find Full Text PDFLetermovir should be first-line cytomegalovirus prophylaxis in lung transplant recipients.
Am J Transplant
January 2025
Division of Pulmonary and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA.
Universal cytomegalovirus (CMV) prophylaxis is recommended for at-risk lung transplant recipients. Valganciclovir is currently the preferred first-line agent. Valganciclovir-related myelosuppression, however, can lead to drug discontinuation or reduction in anti-metabolite immunosuppression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!